JP2024161376A5 - - Google Patents

Download PDF

Info

Publication number
JP2024161376A5
JP2024161376A5 JP2024114477A JP2024114477A JP2024161376A5 JP 2024161376 A5 JP2024161376 A5 JP 2024161376A5 JP 2024114477 A JP2024114477 A JP 2024114477A JP 2024114477 A JP2024114477 A JP 2024114477A JP 2024161376 A5 JP2024161376 A5 JP 2024161376A5
Authority
JP
Japan
Prior art keywords
drawings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024114477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024161376A (ja
Filing date
Publication date
Priority claimed from JP2020531575A external-priority patent/JP7109547B2/ja
Application filed filed Critical
Publication of JP2024161376A publication Critical patent/JP2024161376A/ja
Publication of JP2024161376A5 publication Critical patent/JP2024161376A5/ja
Pending legal-status Critical Current

Links

JP2024114477A 2018-02-15 2024-07-18 真核ゲノム修飾のための操作されたCas9システム Pending JP2024161376A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862631304P 2018-02-15 2018-02-15
US62/631,304 2018-02-15
US201862720525P 2018-08-21 2018-08-21
US62/720,525 2018-08-26
JP2020531575A JP7109547B2 (ja) 2018-02-15 2019-02-15 真核ゲノム修飾のための操作されたCas9システム
PCT/US2019/018335 WO2019161290A1 (en) 2018-02-15 2019-02-15 Engineered cas9 systems for eukaryotic genome modification
JP2022083820A JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022083820A Division JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム

Publications (2)

Publication Number Publication Date
JP2024161376A JP2024161376A (ja) 2024-11-19
JP2024161376A5 true JP2024161376A5 (enExample) 2025-01-14

Family

ID=65995829

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020531575A Active JP7109547B2 (ja) 2018-02-15 2019-02-15 真核ゲノム修飾のための操作されたCas9システム
JP2022083820A Active JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム
JP2024114477A Pending JP2024161376A (ja) 2018-02-15 2024-07-18 真核ゲノム修飾のための操作されたCas9システム

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020531575A Active JP7109547B2 (ja) 2018-02-15 2019-02-15 真核ゲノム修飾のための操作されたCas9システム
JP2022083820A Active JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム

Country Status (11)

Country Link
US (2) US10767193B2 (enExample)
EP (1) EP3752607A1 (enExample)
JP (3) JP7109547B2 (enExample)
KR (3) KR102684890B1 (enExample)
CN (1) CN111902536B (enExample)
AU (3) AU2019222568B2 (enExample)
BR (1) BR112020010479A2 (enExample)
CA (1) CA3084020C (enExample)
IL (2) IL274528B2 (enExample)
SG (1) SG11202007382TA (enExample)
WO (1) WO2019161290A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US11111492B2 (en) * 2017-03-06 2021-09-07 Florida State University Research Foundation, Inc. Genome engineering methods using a cytosine-specific Cas9
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
CA3104856A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
EP3924475A1 (en) 2019-02-15 2021-12-22 Sigma-Aldrich Co. LLC Crispr/cas fusion proteins and systems
MX2021010559A (es) 2019-03-07 2021-12-15 Univ California Polipéptidos efectores de crispr-cas y métodos de uso de estos.
CA3156789A1 (en) 2019-12-17 2021-06-24 Erik Eastlund Genome editing in bacteroides
GB2594339B (en) * 2020-02-14 2023-02-08 Metagenomi Inc Enzymes with RUVC domains
AU2021236230B2 (en) * 2020-03-11 2024-09-26 Sigma-Aldrich Co. Llc High fidelity SpCas9 nucleases for genome modification
EP4632066A3 (en) * 2020-03-31 2025-12-24 Metagenomi, Inc. Class ii, type ii crispr systems
CN112159801B (zh) * 2020-07-13 2022-11-15 复旦大学 SlugCas9-HF蛋白、含有SlugCas9-HF蛋白的基因编辑系统及应用
EP4230737A4 (en) * 2020-09-21 2024-07-24 Korea University Research and Business Foundation NOVEL IMPROVED BASIC EDITING OR REVISION FUSION PROTEIN AND USE THEREOF
US20220145334A1 (en) * 2020-11-06 2022-05-12 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
CN113717960B (zh) * 2021-08-27 2023-07-18 电子科技大学 一种新Cas9蛋白、CRISPR-Cas9基因组定向编辑载体及基因组编辑方法
MX2024002539A (es) 2021-08-27 2024-03-19 Metagenomi Inc Enzimas con dominios ruvc.
KR20240110603A (ko) 2021-11-24 2024-07-15 메타지노미, 인크. 엔도뉴클레아제 시스템
CN114657181B (zh) * 2022-04-01 2023-08-25 安徽大学 一种靶向H1.4的sgRNA以及H1.4基因编辑方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360424A1 (en) 2001-11-26 2003-06-10 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
MY189533A (en) * 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
AU2013355214B2 (en) * 2012-12-06 2017-06-15 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
CA2894668A1 (en) * 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
KR102733409B1 (ko) 2013-06-05 2024-11-21 듀크 유니버시티 Rna-가이드 유전자 편집 및 유전자 조절
US9074199B1 (en) * 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
CA2936646C (en) * 2014-01-24 2024-04-30 North Carolina State University Methods and compositions for sequences guiding cas9 targeting
US11242525B2 (en) * 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
WO2016033298A1 (en) * 2014-08-28 2016-03-03 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
KR102630014B1 (ko) * 2014-10-01 2024-01-25 더 제너럴 하스피탈 코포레이션 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법
DK3272867T3 (da) 2016-06-02 2019-12-02 Sigma Aldrich Co Llc Anvendelse af programmerbare dna-bindingsproteiner til forbedring af målrettet genommodifikation
ES2915562T3 (es) 2016-06-24 2022-06-23 Univ Colorado Regents Métodos para generar bibliotecas combinatorias con código de barras
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
AU2016432443B2 (en) * 2016-12-14 2024-04-18 Stichting Voor De Technische Wetenschappen Thermostable Cas9 nucleases
AU2018299995B2 (en) * 2017-07-11 2021-10-28 Sigma-Aldrich Co. Llc Using nucleosome interacting protein domains to enhance targeted genome modification
KR20250096876A (ko) * 2017-07-31 2025-06-27 리플렉션 바이오테크놀러지스 리미티드 안과 질환을 위한 세포 모델 및 치료요법

Similar Documents

Publication Publication Date Title
JP2024161376A5 (enExample)
JP2024116190A5 (enExample)
JP2023171775A5 (enExample)
JP2024114921A5 (enExample)
JP2022184985A5 (enExample)
JP2025138632A5 (enExample)
JP2023166402A5 (enExample)
JP2024036694A5 (enExample)
JP2024032941A5 (enExample)
JP2023145572A5 (enExample)
JP2023181322A5 (enExample)
JP2024129139A5 (enExample)
JP2024150466A5 (enExample)
JP2024045126A5 (enExample)
JP2025090801A5 (enExample)
JP2025094038A5 (enExample)
JP2025084821A5 (enExample)
JP2024099716A5 (enExample)
JP2025098156A5 (enExample)
JP2024149687A5 (enExample)
JP2023093656A5 (enExample)
JP2024099585A5 (enExample)
JP2023085264A5 (enExample)
JP2023078173A5 (enExample)
JP2024073452A5 (enExample)